[3',3''-dibromo-4',4''-dimethoxy-5',5''-di(methoxycarbonyl)diphenyl]methanone | 159499-98-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [3',3''-dibromo-4',4''-dimethoxy-5',5''-di(methoxycarbonyl)diphenyl]methanone
• 英文别名: 3',3''-dibromo-4',4''-dimethoxy-5',5''-dimethoxycarbonylbenzophenone；3,3'-dibromo-4,4'-dimethoxy-5,5'-bis(methoxycarbonyl)benzophenone；3,3'-dibromo-4,4'-dimethoxy-5,5'bis(methoxycarbonyl)diphenyl ketone；3,3'-dibromo-4,4'-dimethoxy-5,5'-bis(methoxycarbonyl)diphenyl ketone；1,1-Di(5-bromo-4-methoxy-3-methoxycarbonyl)phenyl ketone；methyl 3-bromo-5-(3-bromo-4-methoxy-5-methoxycarbonylbenzoyl)-2-methoxybenzoate
• CAS: 159499-98-6
• 化学式: C₁₉H₁₆Br₂O₇
• 分子量: 516.14
• InChiKey: FYBFULFESMFBIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  88.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  [3',3''-dibromo-4',4''-dimethoxy-5',5''-di(methoxycarbonyl)diphenyl]methanone 在 三甲基氯硅烷 、 sodium hexamethyldisilazane 、 sodium iodide 作用下， 以 乙腈 为溶剂， 反应 69.33h， 生成 3',3''-dibromo-5',5''-dicarboxy-4',4''-dihydroxy-1,1-diphenyl-1-heptene
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Certain Alkenyldiarylmethanes as Anti-HIV-1 Agents Which Act as Non-Nucleoside Reverse Transcriptase Inhibitors

  摘要：

  Several novel alkenyldiarylmethane (ADAM) non-nucleoside HIV-1 reverse transcriptase inhibitors were synthesized. The most potent of these proved to be 3',3''-dibromo-4',4 ''-dimethoxy-5',5 ''-bis(methoxycarbonyl)-1,1-diphenyl-1-heptene (8). ADAM 8 inhibited the cytopathic effect of HIV-1 in CEM cell culture with an EC(50) value of 7.1 mu M and was active against an array of laboratory strains of HIV-1 in CEM-SS and MT-4 cells, but was inactive as an inhibitor of HIV-2. In common with the other known non-nucleoside reverse transcriptase inhibitors, ADAM 8 was an effective inhibitor of HIV-1 reverse transcriptase (IC50 1 mu M) with poly(rC). oligo(dG), but not with poly(rA). oligo(dT), as the template/primer. ADAM 8 was inactive against HIV-1 reverse transcriptases containing non-nucleoside reverse transcriptase inhibitor resistance mutations at residues 101, 106, 108, 139, 181, 188, and 236, while it remained active against enzymes with mutations at residues 74, 98, 100, 103, and at 103/181. An AZT-resistant virus having four mutations in reverse transcriptase was more sensitive to inhibition by ADAM 8 than the wild-type HIV-1. In addition, ADAM 8 displayed synergistic activity with AZT, but lacked synergy with ddI. ADAM 8 or a structurally related analog may therefore be useful as an antiviral agent in combination with AZT or with other NNRTIs that are made ineffective by mutations at residues which do not confer resistance to ADAM 8.

  DOI：

  10.1021/jm960082v
• 作为产物：
  描述：

  3,3'-dibromo-4,4'-dimethoxy-5,5'-bis(methoxycarbonyl)diphenylmethane 在 chromium(VI) oxide 作用下， 以 甲醇 为溶剂， 生成 [3',3''-dibromo-4',4''-dimethoxy-5',5''-di(methoxycarbonyl)diphenyl]methanone
  参考文献：
  名称：

  Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors

  摘要：

  The alkenyldiarylmethanes ( ADAMs) are currently being investigated as non- nucleoside HIV- 1 reverse transcriptase inhibitors ( NNRTIs) of potential value in the treatment of HIV infection and AIDS. During the course of these studies, a number of ADAM analogues have been identified that protect HIV- infected cells from the cytopathic effects of the virus by an unknown, HIV- 1 RT- independent mechanism. Since the phosphodiesterase 4 family is required for HIV infection, the effect of various ADAMs on the activity of PDE4B2 was investigated in an effort to determine if the ADAMs could possibly be targeting phosphodiesterases. Six compounds representative of the ADAM class were tested for inhibition of cAMP hydrolysis by PDE4B2 enzymatic activity. Four ADAMs were found to be weak inhibitors of PDE4B2 and two of them were inactive. The experimental results are consistent with an antiviral mechanism that does not include inhibition of PDE4 isoforms. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.015

文献信息

• The Biological Effects of Structural Variation at the Meta Position of the Aromatic Rings and at the End of the Alkenyl Chain in the Alkenyldiarylmethane Series of Non-Nucleoside Reverse Transcriptase Inhibitors
  作者：Guozhang Xu、Mark Micklatcher、Maximilian A. Silvestri、Tracy L. Hartman、Jennifer Burrier、Mark C. Osterling、Heather Wargo、Jim A. Turpin、Robert W. Buckheit,、Mark Cushman

  DOI：10.1021/jm010212m

  日期：2001.11.1

  In an effort to elucidate a set of structure-activity relationships in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors, a number of modifications were made at two locations: (1) the meta positions of the two aromatic rings and (2) the end of the alkenyl chain. Forty-two new ADAMs were synthesized and evaluated for inhibition of the cytopathic effect of HIV-1(RF)

  为了阐明在烯基二芳基甲烷（ADAM）系列非核苷类逆转录酶抑制剂中的一系列结构活性关系，在两个位置进行了许多修饰：（1）两个芳环的间位和（ 2）烯基链的末端。合成了42种新的ADAM，并评估了它们在CEM-SS细胞培养中对HIV-1（RF）的细胞病变作用的抑制作用以及对HIV-1逆转录酶的抑制作用。发现芳族取代基的大小会影响抗HIV活性，Cl，CH（3）和Br取代基具有最佳活性，而较小（H和F）或较大（I和CF（3）则具有减弱的活性。 ））取代基。还发现烯基链末端的取代基会影响抗病毒活性，具有与甲基或乙基酯基团相关的最大活性，并且由于被高级酯，酰胺，硫化物，亚砜，砜，砜，酯，缩醛，酮，氨基甲酸酯，脲和硫脲取代而导致的活性降低。十二个新的ADAM显示出亚微摩尔EC（50）值，可抑制CEM-SS细胞中HIV-1（RF）的细胞病变作用。将选定的ADAM 19和21与先前发布的ADAM 15和17的
• [EN] ALKENYLDIARYLMETHANE NON-NUCLEOSIDE HIV-1 REVERSE TRANSCRIPTASE INHIBITORS<br/>[FR] INHIBITEURS DE TRANSCRIPTASE INVERSE DU VIH-1 NON NUCLEOSIDIQUES PRESENTANT UNE STRUCTURE ALCENYLDIARYLMETHANE COMMUNE
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：WO1999036384A1

  公开（公告）日：1999-07-22

  (EN) Alkenyldiarylmethane (ADAM) compounds have been found effective as anti-HIV agents. Novel ADAM compounds, their pharmaceutical formulations and a method of using same to treat viral infections are described.(FR) On a découvert que des composés d'alcényldiarylméthane (ADAM) sont efficaces en tant qu'agents anti-VIH. On décrit dans cette invention de nouveaux composés ADAM, des compositions pharmaceutiques contenant ces derniers ainsi qu'un procédé d'utilisation de ces mêmes composés pour traiter des infections virales.

  (中)发现Alkenyldiarylmethane (ADAM)化合物作为抗HIV剂非常有效。本发明描述了新的ADAM化合物，它们的制药配方以及使用它们治疗病毒感染的方法。
• Alkenyldiarylmethane non-nucleoside HIV-1 reverse transcriptase inhibitors
  申请人：——

  公开号：US20030220315A1

  公开（公告）日：2003-11-27

  Alkenyldiarylmethane (ADAM) compounds have been found effective as anti-HIV agents. Novel ADAM compounds, their pharmaceutical formulations and a method of using same to treat viral infections are described.

  Alkenyldiarylmethane (ADAM)化合物已被发现有效作为抗HIV药物。本文描述了新型ADAM化合物、它们的制药配方以及使用它们治疗病毒感染的方法。
• Design, Synthesis, Anti-HIV Activities, and Metabolic Stabilities of Alkenyldiarylmethane (ADAM) Non-nucleoside Reverse Transcriptase Inhibitors
  作者：Maximilian A. Silvestri、Muthukaman Nagarajan、Erik De Clercq、Christophe Pannecouque、Mark Cushman

  DOI：10.1021/jm049916x

  日期：2004.6.1

  The alkenyldiarylmethane (ADAM) HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are effective anti-HIV agents in cell culture. However, the potential clinical utility of the ADAMs is expected to be limited by the presence of methyl ester moieties that are likely to be metabolized by nonspecific esterases in blood plasma to biologically inactive carboxylic acid derivatives. The present investigation was therefore undertaken to investigate the anti-HIV activities of the ADAMs versus HIV-1(IIIB) and HIV-2(ROD) in MT-4 cells and the stabilities of the biologically active ADAMs in rat plasma. The ADAMs displayed a wide range of metabolic stabilities in rat plasma, with half-lives ranging from 0.9 to 76.6 min. A wide assortment of structural modifications was tolerated, with 18 of the 32 compounds tested displaying EC50 values between 0.3 and 3.7 muM versus HIV-1(IIIB) in MT-4 cells, 3 compounds in the EC50 = 13.2-35.4 muM range, and the remaining compounds inactive. Consistent with the mechanism of action of the ADAMs as NNRTIs, they were inactive or displayed comparatively low activity versus HIV-2ROD. The replacement of the two aromatic methyl ester substituents in one of the most active ADAMs (EC50 = 0.6 muM) with two methyl thioester groups resulted in an increase in plasma half-life from 5.8 to 55.3 min, while maintaining the antiviral potency at the EC50 = 1.8 muM level. At the same time, the bis(thioester) modification was less cytotoxic to uninfected MT-4 cells, with a CC50 of >224 muM versus 160 muM for the parent compound.
• Novel Modifications in the Alkenyldiarylmethane (ADAM) Series of Non-Nucleoside Reverse Transcriptase Inhibitors
  作者：Agustin Casimiro-Garcia、Mark Micklatcher、Jim A. Turpin、Tracy L. Stup、Karen Watson、Robert W. Buckheit、Mark Cushman

  DOI：10.1021/jm990343b

  日期：1999.11.1

  In an effort to obtain more insight into the interaction between HIV-1 reverse transcriptase and the alkenyldiarylmethanes (ADAMs), a new series of compounds has been synthesized and evaluated for inhibition of HIV-1 replication. The modifications reported in this new series include primarily changes to the alkenyl chain. The most potent compound proved to be methyl 3', 3 "-dibromo-4',4 "-dimethoxy-5',5 "-bis(methoxycarbonyl)-6,6-diphenyl-5-hexanoate (28), which displayed an EC50 of 1.3 nM for inhibition of the cytopathic effect of HIV-1(RF) in CEM-SS cells. ADAM 28 inhibited HIV-1 reverse transcriptase with an IC50 of 0.3 mu M. Mutations that conferred greater than 10-fold resistance to ADAM 28 clustered at residues Val 106, Val 179, Tyr 181, and Tyr 188. Results derived from this series indicate that ADAMs containing chlorines in the aromatic rings might bind to HIV-1 reverse transcriptase in a slightly different mode when compared with those analogues incorporating bromine in the aromatic rings.